@article{3206694,
    title = "Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients.",
    author = "Gribabis, D. A. and Panayiotidis, P. and Boussiotis, V. A. and Hannoun, C. and Pangalis, G. A.",
    journal = "Acta Haematologica",
    year = "1994",
    volume = "91",
    number = "3",
    pages = "115--118",
    issn = "0001-5792, 1421-9662",
    doi = "10.1159/000204315",
    keywords = "Humans, Female, Male, Adult, Vaccination, Aged, Middle Aged, Antibody Formation, Hypersensitivity, Delayed/etiology, Hypersensitivity, Immediate/etiology, Influenza Vaccines/*administration & dosage/adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell/*immunology",
    abstract = "The clinical reaction and the immunological response to influenza virus vaccine were studied in 43 B-cell chronic lymphocytic leukaemia patients. The Vaxigrip vaccine  was administered containing the antigens A/Ghizhou/54/89, A/Singapore/6/86, and  B/Yamagata/16/88. The side-effects observed were minimal and well tolerated.  Antibody production with titres > 1:20 on day 15 was observed at least for one  antigen in 35 patients (81%). In 23 of them (63%) this response was retained on days  30 and 60. Patients with IgG levels (< 700 mg/dl) responded less well as compared to  those having normal IgG levels (> 700 mg/dl)."
}